Invivyd (IVVD)
NASDAQ:IVVD
Want to see IVVD full AI Analyst Report?
Earnings Data
Report Date
Aug 19, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.12Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents strong commercial momentum (PEMGARDA +22% YoY), advancing pivotal trial progress with encouraging safety signals (IDMC reduced monitoring), confirmed neutralization versus a recent Omicron subvariant, an expanding discovery pipeline, and a robust cash position after an April ATM raise. Near-term challenges include elevated clinical spend and burn during the pivotal, continued uncertainty around regulatory outcomes and efficacy readouts driven by event rates, declining COVID vaccine revenue, and imperfect external surveillance and media traction. On balance, concrete operational and scientific progress and expected high efficacy positioning outweigh the near-term financial and market uncertainties.Company Guidance
PEMGARDA Revenue Growth
PEMGARDA grew 22% year-over-year in 1Q2026 versus 1Q2025; leading indicators show continued growth and the company is scaling direct-to-consumer and AI channels to further increase disease and brand awareness.
DECLARATION Trial Progress & Recruitment
Pivotal DECLARATION program upsized in April; recruitment into the upsized cohort proceeded faster than internal expectations, was temporarily slowed to align with expected summer case rates, has resumed at full speed and is expected to finish imminently, keeping the program on schedule.
Encouraging Safety Signal — Reduced Post‑Dose Monitoring
Independent Data Monitoring Committee recommended reducing post-dose monitoring for VYD2311 from 2 hours to 30 minutes after review of unblinded safety data — interpreted as an indicator of favorable tolerability and operational simplicity.
Neutralization vs Omicron BA.3.2 and Variant Coverage
Formally confirmed virus neutralization of Invivyd medicines against Omicron BA.3.2 and reported continued attractive neutralization data across relevant SARS‑CoV‑2 variants, supporting the company's RBD-targeting strategy.
Pipeline Expansion & Near-Term Studies
Disclosed an expanding early discovery pipeline (measles, RSV, mumps, rubella, Lyme disease, etc.) and announced LIBERTY study will open soon to assess combined vaccine + monoclonal antibody immunology and tolerability.
Commercial Readiness and Strong Cash Position
Investments made to prepare for potential VYD2311 commercialization leveraging PEMGARDA infrastructure; company reports a strong cash position after additional April ATM offering and expects R&D spend to normalize as the pivotal trial winds down.
Efficacy & Public‑Health Modeling
Company modeling and correlative analyses highlight lower reactogenicity for monoclonal antibodies versus vaccines (citing Sanofi COMPARE reactogenicity signals: high rates of short symptom days for vaccines) and state their VYD2311 dosing justification would conceptually generate ~70%–90% protection; modeling also notes that even low VE (10%–15%) for a low-reactogenicity monoclonal can yield net symptomatic benefit at the population level.
IVVD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IVVD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 05, 2026 | $1.71 | $1.74 | +1.75% |
Nov 06, 2025 | $1.52 | $1.54 | +1.32% |
Aug 14, 2025 | $0.80 | $0.71 | -11.25% |
May 15, 2025 | $0.84 | $0.70 | -16.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Invivyd (IVVD) report earnings?
Invivyd (IVVD) is schdueled to report earning on Aug 19, 2026, Before Open (Confirmed).
What is Invivyd (IVVD) earnings time?
Invivyd (IVVD) earnings time is at Aug 19, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IVVD EPS forecast?
IVVD EPS forecast for the fiscal quarter 2026 (Q2) is -0.1.